PD-1/PD-L1抑制剂引起免疫相关性肺炎的研究进展

Research progress of immune-related pneumonia caused by PD-1/PD-L1 inhibitor

程序性死亡蛋白-1/程序性死亡蛋白配体-1抑制剂引起的免疫相关性肺炎发生率低,但风险较高。有肺部基础疾病与既往接受过胸部放疗的非小细胞肺癌患者更易发生肺炎,但其临床症状不典型,导致患者生存获益下降。及早延缓免疫疗法并合理使用糖皮质激素与免疫抑制剂可缓解临床症状,改善预后。

The incidence of immune-related pneumonia caused by programmed death-1/programmed death ligand-1 inhibitors is low,but the risk is high.Patients with non-small cell lung cancer who have pre-existing lung diseases or have received chest radiotherapy are more likely to develop pneumonia,but their clinical symptoms are not typical,which reduces the survival benefit of patients.Delaying immunotherapy early and rationally using glucocorticoids and immunosuppressants can relieve clinical symptoms and improve prognosis.